Skip to main content

mAbs & Antibody-Related Therapies

For formulation development of monoclonal antibody and related therapeutics, Labcorp has developed a focused formulation development workflow to minimize analytical load and reduce sample requirements. This workflow still provides a comprehensive understanding of degradation routes and the stabilizing effects of excipients to enable formulation development.
A microscopic image of an antibody

Our approach

  • Liquid chromatography-mass spectrometry multiple attribute monitoring (LC-MS MAM) to provide primary structure/post-translational modification data

  • Surface plasmon resonance (SPR) ligand binding to provide structure/function data

  • Reduced analytical workflows of standard methods of size exclusion chromatography coupled with multiple-angle light scattering (SEC-MALS), total soluble protein determination and dynamic light scattering (DLS) to understand colloidal/conformational stability, oligomerization, and aggregation

  • pH screen to evaluate colloidal and confirmational stability for optimal pH conditions. The optimal pH is then incorporated into the experimental testing of selected well-established excipients

To further streamline the study, in line with ICH Q8 (R2) and QbD, our process incorporates a design of experiment (DoE) statistical approach to evaluate the potential of stabilizing excipients when exposed to thermal stress. Using DoE provides the maximum amount of data for the minimum number of samples and hence also reduces the analytical load. The outcome of these studies is a lead formulation for subsequent additional stability testing, such as real-time, accelerated and/or forced degradation.

Pre-formulation resources

Article

Forced degradation of biopharmaceuticals: Protein stress testing

Info Sheet

Formulation development: The key to product stability